Aurinia Pharmaceuticals Inc (AUPH)

Currency in USD
16.860
-0.470(-2.71%)
Closed·
17.195+0.335(+1.99%)
·
Advertisement
Earnings results expected in 4 days
AUPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.81017.310
52 wk Range
11.88519.250
Key Statistics
Prev. Close
16.86
Open
17.27
Day's Range
16.81-17.31
52 wk Range
11.885-19.25
Volume
649.24K
Average Volume (3m)
954.85K
1-Year Change
41.7998%
Book Value / Share
4.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AUPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.000
Upside
+6.76%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 18.000
(+6.76% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy18.00+6.76%17.00Maintain21/10/2026
Bloom Burton & Co.
Buy21.00+24.56%-Upgrade20/08/2026
RBC Capital
Hold16.00-5.10%15.00Maintain07/08/2026
Leerink Partners
Hold16.00-5.10%-Downgrade03/12/2025
Jefferies
Buy21.00+24.56%10.00Upgrade07/11/2025

Aurinia Pharmaceuticals Inc Earnings Call Summary for Q4/2025

  • Q4 EPS of $1.53 vastly exceeded forecast of $0.15 (920% beat); revenue rose 29% YoY to $77.1M, surpassing estimates of $74.41M.
  • LUPKYNIS drove 95.7% of revenue; net income surged to $210.8M from $1.4M YoY, boosted by deferred tax asset valuation allowance release.
  • Company projects 2026 LUPKYNIS sales of $305-315M (12-16% growth); advancing Aritinercept biologic for autoimmune disease treatment.
  • Strong balance sheet with 5.76 current ratio, 80% gross margin, and $45.7M operating cash flow (up 52% YoY); stock rose 3.67% pre-market.
  • Key risk: 95.7% revenue concentration in single product exposes company to market shifts, regulatory challenges, and emerging competition.
Last Updated: 26/02/2026, 14:34
Read Full Transcript

Earnings

Latest Release
06/08/2026
EPS / Forecast
0.28 / 0.23
Revenue / Forecast
83.2M / 80.56M
EPS Revisions
Last 90 days

Compare AUPH to Peers and Sector

Metrics to compare
AUPH
Peers
Sector
Relationship
P/E Ratio
7.1x18.4x−0.3x
PEG Ratio
0.02−0.010.00
Price/Book
3.6x4.7x2.6x
Price / LTM Sales
7.2x5.2x2.9x
Upside (Analyst Target)
6.8%112.1%65.2%
Fair Value Upside
Unlock16.2%9.1%Unlock

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Employees
128

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
19.58M14.72%330.10M
Other Institutional Investors
80.62M60.59%1.36B
Public Companies & Retail Investors
32.85M24.69%553.90M
Total
133.05M100.00%2.24B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Tang Capital Management, LLC9.80%13,044,106219,924
BlackRock, Inc.6.16%8,193,085138,135

People Also Watch

19.73
ACAD
-2.86%
22.74
EVER
-3.60%
64.76
BALL
-1.60%
117.18
SIG
+0.21%
48.130
RIGL
-1.49%

FAQ

What Is the Aurinia (NASDAQ: AUPH) Share Price Today?

The Aurinia stock price today is 16.860 USD.

What Stock Exchange Does Aurinia (AUPH) Trade On?

Aurinia is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Aurinia?

The stock symbol (also called a 'ticker') for Aurinia is "AUPH."

What Is the Current Aurinia Market Capitalisation?

As of today, Aurinia (NASDAQ: AUPH) market cap is 2.240B USD.

What Is Aurinia's (AUPH) Earnings Per Share (TTM)?

The Aurinia EPS is currently 2.39 (Trailing Twelve Months).

When Is the Next Aurinia Earnings Date?

Aurinia's next earnings report will be released on 29/10/2026.

Is AUPH a Buy or Sell From a Technical Analyst Perspective?

Based on today's Aurinia moving averages and other technical indicators, the daily buy/sell signal for AUPH stock is Strong Buy.

How Many Times Has Aurinia Stock Split?

Aurinia has split 1 times. (See the AUPH stock split history page for full effective split date and price information.)

How Many Employees Does Aurinia Have?

Aurinia has 128 employees, based on their latest Companies House report.

What is the current trading status of Aurinia (NASDAQ: AUPH)?

As of 25/10/2026, Aurinia (AUPH) is trading at a share price of 16.860 USD, with a previous close of 16.860 USD. The stock has fluctuated within a day range of 16.810 USD to 17.310 USD, while its 52-week range spans from 11.885 USD to 19.250 USD.

What Is Aurinia (AUPH) Price Target According to Analysts?

The average 12-month price target for Aurinia is 18.000 USD, with a high estimate of 21 USD and a low estimate of 16 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +6.76% Upside potential.

What Is the AUPH Premarket Price?

AUPH's last pre-market stock price is 17.130 USD. The pre-market share volume is 1,730.000, and the stock has decreased by -0.200, or -1.150%.

What Is the AUPH After Hours Price?

AUPH's last after hours stock price is 17.195 USD, the stock has decreased by 0.335, or 1.990%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.